Biotech entity
Every one of those 1 sits in a single category, pharma. S&P Global is most often covered alongside Avidity Biosciences, Inc., which appears in 1 of these 1 story. The tracked stories average 2 original sources each. S&P Global appears in 1 tracked Biotech story from March 3, 2026.
Last mentioned: 3h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. S&P Global is most often covered alongside Avidity Biosciences, Inc., which appears in 1 of these 1 story. The tracked stories average 2 original sources each. S&P Global appears in 1 tracked Biotech story from March 3, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering S&P Global. Shared-story counts are live from our verified record — not editorial picks.
Avidity Biosciences (RNAM) has been removed from the S&P Global BMI and S&P TMI indices as part of a periodic rebalancing. The exclusion from these broad market benchmarks is expected to trigger mandatory selling by passive investment funds and ETFs tracking the indices.
Source: S&p Capital Iq (fr) · S&p Capital Iq (fr)
S&P Global is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
